Unformatted text preview: Pfizer's insulin was doubted by doctors so diabetics who used the inhaler had to have routine appointments. Because of this, insurances would not cover but a small percent of the cost. If Pfizer was to have a second attempt in this market, I would suggest taking another look at what they did wrong and try to fix the current problems. Since there are other companies who have already been successful in the market since Pfizer's first attempt, I would advise him to use those companies' techniques as a foundation. They offer competition which is a key to success in both companies....
View Full Document
- Spring '09
- Insulin resistance, Hypodermic needle